-
A Review of the Great Journey of Capecitabine that Has Been Marketed in China for 20 Years
PharmaSources/Wang Hong
November 10, 2020
Fluorouracil has been used in clinical treatment for more than half a century. Capecitabine, an oral prodrug of fluorouracil, is very convenient to use and is one of the classical chemotherapeutics widely used in clinical practice.
-
Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer
PRNewswire
December 12, 2024
Menarini Group and MEDSIR Present the Phase III Study ADELA: A New Therapeutic Strategy for Advanced Breast Cancer
-
With personalized medicine, a shelved cancer drug could get another shot
WorldPharmaNews
February 09, 2022
A study by Virginia Commonwealth University Massey Cancer Center researchers published in today's print edition of Molecular Cancer Therapeutics shows that triplatin is effective against triple negative breast cancer...
-
Immune-Based Therapy Shows Promise Against Advanced Breast Cancers
drugs.com
February 09, 2022
An experimental therapy that harnesses the body's tumor-fighting immune cells...
-
Puma Biotechnology’s NERLYNX Included in Two Important NCCN Clinical Practice Guideline Updates for the Treatment of Breast Cancer
FirstWordPharma
January 13, 2022
Puma Biotechnology, Inc. (Nasdaq: PBYI), a biopharmaceutical company, announced that the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) for the treatment...
-
Metabolic vulnerabilities could be new targets for metastatic breast cancer
FirstWordPharma
January 13, 2022
Metabolic differences could explain why some metastatic breast cancer cells rapidly generate tumors after migrating from primary tumors to the brain, while others linger for months or years before forming these secondary tumors...
-
Overall Breast Cancer Incidence Decreased From 1999 to 2018
drugs.com
January 13, 2022
The incidence of breast cancer decreased overall from 1999 to 2018, but incidence increased among women aged 20 to 39 years and for non-Hispanic...
-
Tailored Strategies Can Up Depression Referrals in Breast Cancer
drugs
January 04, 2022
For patients with newly diagnosed breast cancer, tailored strategies for implementation of routine depression screening result in a greater proportion of referrals to behavioral care, according to a study published in the Jan. 4 issue of the Journal of th
-
Breast Cancer Survival Up With Access to Integrative Therapies
drugs
December 29, 2021
Institutional involvement in integrative oncology may increase survival for breast cancer patients, according to a study published online Dec. 18 in the Journal of Oncology.
-
Regor Therapeutics Announces U.S. FDA Authorization to Conduct Regor's First-in-Human Clinical Trial with the Next Generation Targeted Inhibitor RGT-419B for Oncology
prnasia
December 28, 2021
On December 23, Regor Therapeutics, a clinical-stage biotech company, announced authorization from the US Food and Drug Administration (FDA) to proceed with Regor's Phase 1 clinical development plans for RGT-419B.